[go: up one dir, main page]

TW201705965A - β2GPI基因表現抑制RNAi醫藥組合物 - Google Patents

β2GPI基因表現抑制RNAi醫藥組合物 Download PDF

Info

Publication number
TW201705965A
TW201705965A TW105122521A TW105122521A TW201705965A TW 201705965 A TW201705965 A TW 201705965A TW 105122521 A TW105122521 A TW 105122521A TW 105122521 A TW105122521 A TW 105122521A TW 201705965 A TW201705965 A TW 201705965A
Authority
TW
Taiwan
Prior art keywords
group
compound
alkenyl
carbon atoms
double
Prior art date
Application number
TW105122521A
Other languages
English (en)
Chinese (zh)
Inventor
Kazutaka Nagatomo
Kazuhiro Masuda
Minako Kanda
Yoji Yamada
Hiroto Iwai
Tomoyuki Naoi
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of TW201705965A publication Critical patent/TW201705965A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TW105122521A 2015-07-15 2016-07-15 β2GPI基因表現抑制RNAi醫藥組合物 TW201705965A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015141352A JP2018150239A (ja) 2015-07-15 2015-07-15 β2GPI遺伝子発現抑制RNAi医薬組成物

Publications (1)

Publication Number Publication Date
TW201705965A true TW201705965A (zh) 2017-02-16

Family

ID=57757451

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105122521A TW201705965A (zh) 2015-07-15 2016-07-15 β2GPI基因表現抑制RNAi醫藥組合物

Country Status (3)

Country Link
JP (1) JP2018150239A (ja)
TW (1) TW201705965A (ja)
WO (1) WO2017010573A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3323893A4 (en) * 2015-07-16 2019-03-27 Kyowa Hakko Kirin Co., Ltd. BETA2GPI GENE EXPRESSION-INHIBITING NUCLEIC ACID COMPLEX
CA2998810A1 (en) 2015-09-17 2017-03-23 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
SMT202200252T1 (it) * 2015-12-22 2022-07-21 Modernatx Inc Composti e composizioni per il rilascio intracellulare di agenti
WO2019027009A1 (ja) * 2017-08-02 2019-02-07 協和発酵キリン株式会社 核酸複合体
US11066355B2 (en) 2019-09-19 2021-07-20 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
CN117263882B (zh) * 2023-11-21 2024-02-23 深圳瑞吉生物科技有限公司 一种阳离子脂质化合物、包含其的组合物及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010054406A1 (en) * 2008-11-10 2010-05-14 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics

Also Published As

Publication number Publication date
JP2018150239A (ja) 2018-09-27
WO2017010573A1 (ja) 2017-01-19

Similar Documents

Publication Publication Date Title
TW201726600A (zh) 陽離子性脂質
CN110799492B (zh) 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
TW201705965A (zh) β2GPI基因表現抑制RNAi醫藥組合物
TWI576113B (zh) 陽離子性脂質
CA2665225C (en) Lipid containing formulations
ES3017428T3 (en) Ionizable cationic lipids for lipid nanoparticles
JP2019508371A (ja) 薬剤の細胞内送達のための化合物および組成物
EP2319519B1 (en) Composition for inhibiting expression of target gene
TW201330874A (zh) 含有陽離子性脂質之組合之脂質奈米粒子
WO2018225871A1 (ja) カチオン性脂質としての化合物
KR20240122872A (ko) 지질 나노입자에 사용하기 위한 플루오르화 양이온성 지질
TW202337498A (zh) 用於rna遞送之可離子化陽離子脂質
KR20170012366A (ko) CKAP5 유전자 발현 억제 RNAi 의약 조성물
WO2025223309A1 (zh) 一种脂质化合物、包含其的脂质纳米颗粒及其应用
TW201619137A (zh) 陽離子性脂質
KR20240167649A (ko) 아미노 지질 화합물, 이의 제조 방법, 이의 조성물 및 이의 용도
JP2018065789A (ja) カチオン性脂質
TW201726614A (zh) 作為陽離子性脂質之化合物
JP7043411B2 (ja) カチオン性脂質としての化合物
TW202517607A (zh) 脂質和脂質奈米顆粒